This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Feb;45(4):572-573.

doi: 10.1111/apt.13881.

Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection

M Zamani¹, J Shokri-Shirvani², V Zamani³

Affiliations

Affiliations

¹ Student Research Committee, School of Medicine, Babol University of Medical Sciences, Babol, Iran.
² Department of Internal Medicine, Rohani Hospital, Babol University of Medical Sciences, Babol, Iran.
³ Vice-Chancellery for Health, Babol University of Medical Sciences, Babol, Iran.

PMID: 28074507
DOI: 10.1111/apt.13881

Comment

Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection

M Zamani et al. Aliment Pharmacol Ther. 2017 Feb.

. 2017 Feb;45(4):572-573.

doi: 10.1111/apt.13881.

Authors

M Zamani¹, J Shokri-Shirvani², V Zamani³

Affiliations

¹ Student Research Committee, School of Medicine, Babol University of Medical Sciences, Babol, Iran.
² Department of Internal Medicine, Rohani Hospital, Babol University of Medical Sciences, Babol, Iran.
³ Vice-Chancellery for Health, Babol University of Medical Sciences, Babol, Iran.

PMID: 28074507
DOI: 10.1111/apt.13881

No abstract available

PubMed Disclaimer

Comment in

Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply.
Chen PY, Wu MS, Liou JM. Chen PY, et al. Aliment Pharmacol Ther. 2017 Feb;45(4):573. doi: 10.1111/apt.13909. Aliment Pharmacol Ther. 2017. PMID: 28074519 No abstract available.

Comment on

Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection.
Chen PY, Wu MS, Chen CY, Bair MJ, Chou CK, Lin JT, Liou JM; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Chen PY, et al. Aliment Pharmacol Ther. 2016 Sep;44(5):427-37. doi: 10.1111/apt.13712. Epub 2016 Jun 30. Aliment Pharmacol Ther. 2016. PMID: 27363687

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations